Journal for ImmunoTherapy of Cancer

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma
Howard L Kaufman, Carl E Ruby, Tasha Hughes, Craig L Slingluff

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 11; DOI: 10.1186/2051-1426-2-11
The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer
Ross Stewart, Scott A Hammond, Michael Oberst, Robert W Wilkinson

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 29; DOI: 10.1186/s40425-014-0029-x
Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors
By Gan Zhao, John P Vasilakos, Debra Tross, Dmitri Smirnov, Dennis M Klinman

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 12; DOI: 10.1186/2051-1426-2-12
Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study
Uwe Trefzer, Ralf Gutzmer, Tabea Wilhelm, Florian Schenck, Katharina C Kähler, Volkmar Jacobi, Klaus Witthohn, Hans Lentzen, Peter Mohr

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 27; DOI: 10.1186/s40425-014-0027-z
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer
Raju R Raval, Andrew B Sharabi, Amanda J Walker, Charles G Drake, Padmanee Sharma

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 14; DOI: 10.1186/2051-1426-2-14
Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab
Saskia JAM Santegoets, Anita GM Stam, Sinéad M Lougheed, Helen Gall, Karin Jooss, Natalie Sacks, Kristen Hege, Israel Lowy, Rik J Scheper, Winald R Gerritsen, Alfons JM van den Eertwegh, Tanja D de Gruijl

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 31; DOI: 10.1186/s40425-014-0031-3
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Paolo A Ascierto, David H Munn, Anna K Palucka, Paul M Sondel

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 15; DOI: 10.1186/2051-1426-2-15
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
Janice P Dutcher, Douglas J Schwartzentruber, Howard L Kaufman, Sanjiv S Agarwala, Ahmad A Tarhini, James N Lowder, Michael B Atkins

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 26; DOI: 10.1186/s40425-014-0026-0
Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8⁺ T cells
Michael J McNamara, Melissa J Kasiewicz, Stefanie N Linch, Christopher Dubay, William L Redmond

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 28; DOI: 10.1186/s40425-014-0028-y
Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses
Andrew Zloza, Dae Won Kim, Seunghee Kim-Schulze, Michael C Jagoda, Vladia Monsurro, Francesco M Marincola, Howard L Kaufman

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 1; DOI: 10.1186/2051-1426-2-1

Main menu

Journal for ImmunoTherapy of Cancer

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Journal for ImmunoTherapy of Cancer

Pages